Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour BioMed to Start US Trials of Novel Bispecific for Solid Tumor Cancers

publication date: Jun 27, 2022

Harbour BioMed was approved to start US Phase I trials of its B7H4x4-1BB bispecific antibody in patients with solid tumor cancers. HBM said HBM7008 is a first-in-class bispecific antibody targeting B7H4 and 4-1BB that activates T cells via 4-1BB only in a B7H4 positive tumor microenvironment. B7H4 is overexpressed on a variety of solid malignancies, including breast, ovarian, endometrial, and non-small cell lung cancers. In May, HBM started Australian trials of the bispecific. Harbor BioMed is headquartered in Cambridge, MA, with facilities in Rotterdam and Suzhou. More details....

Stock Symbol: (HK: 02142)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital